Logo: to the web site of Uppsala University

uu.sePublications from Uppsala University
Planned maintenance
A system upgrade is planned for 10/12-2024, at 12:00-13:00. During this time DiVA will be unavailable.
Change search
Refine search result
1 - 49 of 49
CiteExportLink to result list
Permanent link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Rows per page
  • 5
  • 10
  • 20
  • 50
  • 100
  • 250
Sort
  • Standard (Relevance)
  • Author A-Ö
  • Author Ö-A
  • Title A-Ö
  • Title Ö-A
  • Publication type A-Ö
  • Publication type Ö-A
  • Issued (Oldest first)
  • Issued (Newest first)
  • Created (Oldest first)
  • Created (Newest first)
  • Last updated (Oldest first)
  • Last updated (Newest first)
  • Disputation date (earliest first)
  • Disputation date (latest first)
  • Standard (Relevance)
  • Author A-Ö
  • Author Ö-A
  • Title A-Ö
  • Title Ö-A
  • Publication type A-Ö
  • Publication type Ö-A
  • Issued (Oldest first)
  • Issued (Newest first)
  • Created (Oldest first)
  • Created (Newest first)
  • Last updated (Oldest first)
  • Last updated (Newest first)
  • Disputation date (earliest first)
  • Disputation date (latest first)
Select
The maximal number of hits you can export is 250. When you want to export more records please use the Create feeds function.
  • 1.
    Abu Sabaa, Amal
    et al.
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Disciplinary Domain of Medicine and Pharmacy, research centers etc., Centre for Research and Development, Gävleborg. Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology, Cancer Immunotherapy.
    Mörth, Charlott
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Disciplinary Domain of Medicine and Pharmacy, research centers etc., Centre for Clinical Research Sörmland. Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology, Cancer Immunotherapy.
    Berglund, Mattias
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology, Cancer Immunotherapy.
    Hashemi, Jamileh
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology, Cancer Immunotherapy.
    Amini, Rose-Marie
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology, Cancer Immunotherapy.
    Freyhult, Eva
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Medical Sciences, Cancer Pharmacology and Computational Medicine. Uppsala University, Science for Life Laboratory, SciLifeLab. Uppsala University, Disciplinary Domain of Science and Technology, Biology, Department of Cell and Molecular Biology.
    Kamali-Moghaddam, Masood
    Uppsala University, Science for Life Laboratory, SciLifeLab. Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology, Molecular Tools and Functional Genomics.
    Robelius, Anna
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Medical Sciences, Haematology.
    Enblad, Gunilla
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology, Cancer Immunotherapy.
    T-cell Leukaemia/Lymphoma Protein 1A (TCL1A) In Diffuse Large B-cell lymphoma (DLBCL)Manuscript (preprint) (Other academic)
  • 2.
    Abu Sabaa, Amal
    et al.
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Disciplinary Domain of Medicine and Pharmacy, research centers etc., Centre for Research and Development, Gävleborg. Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology, Cancer Immunotherapy.
    Mörth, Charlott
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Disciplinary Domain of Medicine and Pharmacy, research centers etc., Centre for Clinical Research Sörmland. Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology, Cancer Immunotherapy.
    Molin, Daniel
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology, Cancer Immunotherapy.
    Freyhult, Eva
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Medical Sciences, Cancer Pharmacology and Computational Medicine. Uppsala University, Science for Life Laboratory, SciLifeLab. Uppsala University, Disciplinary Domain of Science and Technology, Biology, Department of Cell and Molecular Biology.
    Kamali-Moghaddam, Masood
    Uppsala University, Science for Life Laboratory, SciLifeLab. Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology, Molecular Tools and Functional Genomics.
    Robelius, Anna
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Medical Sciences, Haematology.
    Enblad, Gunilla
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology, Cancer Immunotherapy.
    Plasma Protein Profiling using Multiplex Extension Assay in Diffuse large B-cell lymphoma (DLBCL) treated with R-CHOP: A descriptive studyManuscript (preprint) (Other academic)
  • 3.
    Borgenvik, Anna
    et al.
    Uppsala University, Science for Life Laboratory, SciLifeLab. Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology, Neurooncology and neurodegeneration.
    Holmberg, Karl O.
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology. Uppsala University, Science for Life Laboratory, SciLifeLab.
    Bolin, Sara
    Uppsala University, Science for Life Laboratory, SciLifeLab. Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology.
    Zhao, Miao
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology, Neurooncology and neurodegeneration. Uppsala University, Science for Life Laboratory, SciLifeLab.
    Savov, Vasil
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology. Uppsala University, Science for Life Laboratory, SciLifeLab.
    Rosén, Gabriela
    Uppsala University, Science for Life Laboratory, SciLifeLab. Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology, Neurooncology and neurodegeneration.
    Hutter, Sonja
    Uppsala University, Science for Life Laboratory, SciLifeLab. Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology, Neurooncology and neurodegeneration.
    Garancher, Alexandra
    Sanford Burnham Prebys Med Discovery Inst, Tumor Initiat & Maintenance Program, San Diego, CA USA..
    Rahmanto, Aldwin Suryo
    Karolinska Inst, Dept Cell & Mol Biol, Stockholm, Sweden..
    Bergström, Tobias
    Uppsala University, Science for Life Laboratory, SciLifeLab. Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology, Neurooncology and neurodegeneration.
    Olsen, Thale Kristin
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology, Neurooncology and neurodegeneration. Uppsala University, Science for Life Laboratory, SciLifeLab.
    Mainwaring, Oliver
    Uppsala University, Science for Life Laboratory, SciLifeLab. Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology, Neurooncology and neurodegeneration.
    Sattanino, Damiana
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology. Uppsala University, Science for Life Laboratory, SciLifeLab.
    Verbaan, Annemieke D.
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology. Uppsala University, Science for Life Laboratory, SciLifeLab.
    Rusert, Jessica M.
    Sanford Burnham Prebys Med Discovery Inst, Tumor Initiat & Maintenance Program, San Diego, CA USA..
    Sundström, Anders
    Uppsala University, Science for Life Laboratory, SciLifeLab. Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology, Neurooncology and neurodegeneration.
    Ballester Bravo, Mar
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology, Neurooncology and neurodegeneration. Uppsala University, Science for Life Laboratory, SciLifeLab.
    Dang, Yonglong
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology. Uppsala University, Science for Life Laboratory, SciLifeLab.
    Wenz, Amelie S.
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology. Uppsala University, Science for Life Laboratory, SciLifeLab.
    Richardson, Stacey
    Newcastle Univ Ctr Canc, Wolfson Childhood Canc Res Ctr, Translat & Clin Res Inst, Newcastle Upon Tyne, Tyne & Wear, England..
    Fotaki, Grammatiki
    Uppsala University, Science for Life Laboratory, SciLifeLab. Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology.
    Hill, Rebecca M.
    Newcastle Univ Ctr Canc, Wolfson Childhood Canc Res Ctr, Translat & Clin Res Inst, Newcastle Upon Tyne, Tyne & Wear, England..
    Dubuc, Adrian M.
    Hosp Sick Children, Arthur & Sonia Labatt Brain Tumor Res Ctr, Toronto, ON, Canada..
    Kalushkova, Antonia
    Uppsala University, Science for Life Laboratory, SciLifeLab. Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology, Cancer precision medicine.
    Remke, Marc
    Hosp Sick Children, Arthur & Sonia Labatt Brain Tumor Res Ctr, Toronto, ON, Canada..
    Čančer, Matko
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology. Uppsala University, Science for Life Laboratory, SciLifeLab.
    Jernberg Wiklund, Helena
    Uppsala University, Science for Life Laboratory, SciLifeLab. Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology, Cancer precision medicine.
    Giraud, Geraldine
    Uppsala University, Science for Life Laboratory, SciLifeLab. Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology, Neurooncology and neurodegeneration.
    Chen, Xingqi
    Uppsala University, Science for Life Laboratory, SciLifeLab. Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology, Molecular Tools and Functional Genomics.
    Taylor, Michael D.
    Hosp Sick Children, Arthur & Sonia Labatt Brain Tumor Res Ctr, Toronto, ON, Canada..
    Sangfelt, Olle
    Karolinska Inst, Dept Cell & Mol Biol, Stockholm, Sweden..
    Clifford, Steven C.
    Newcastle Univ Ctr Canc, Wolfson Childhood Canc Res Ctr, Translat & Clin Res Inst, Newcastle Upon Tyne, Tyne & Wear, England..
    Schueller, Ulrich
    Univ Med Ctr Hamburg Eppendorf, Inst Neuropathol, Hamburg, Germany.;Univ Med Ctr Hamburg Eppendorf, Dept Paediat Hematol & Oncol, Hamburg, Germany.;Res Inst Childrens Canc Ctr Hamburg, Hamburg, Germany..
    Wechsler-Reya, Robert J.
    Sanford Burnham Prebys Med Discovery Inst, Tumor Initiat & Maintenance Program, San Diego, CA USA..
    Weishaupt, Holger
    Uppsala University, Science for Life Laboratory, SciLifeLab. Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology, Neurooncology and neurodegeneration.
    Swartling, Fredrik J.
    Uppsala University, Science for Life Laboratory, SciLifeLab. Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology, Neurooncology and neurodegeneration.
    Dormant SOX9-Positive Cells Facilitate MYC-Driven Recurrence of Medulloblastoma2022In: Cancer Research, ISSN 0008-5472, E-ISSN 1538-7445, Vol. 82, no 24, p. 4586-4603Article in journal (Refereed)
    Abstract [en]

    Relapse is the leading cause of death in patients with medulloblas-toma, the most common malignant pediatric brain tumor. A better understanding of the mechanisms underlying recurrence could lead to more effective therapies for targeting tumor relapses. Here, we observed that SOX9, a transcription factor and stem cell/glial fate marker, is limited to rare, quiescent cells in high-risk medulloblastoma with MYC amplification. In paired primary-recurrent patient samples, SOX9-positive cells accumulated in medulloblastoma relapses. SOX9 expression anti-correlated with MYC expression in murine and human medulloblastoma cells. However, SOX9-positive cells were plastic and could give rise to a MYC high state. To follow relapse at the single-cell level, an inducible dual Tet model of medulloblastoma was developed, in which MYC expression was redirected in vivo from treatment-sensitive bulk cells to dormant SOX9-positive cells using doxycycline treatment. SOX9 was essential for relapse initiation and depended on suppression of MYC activity to promote therapy resistance, epithelial-mesenchymal transition, and immune escape. p53 and DNA repair pathways were downregulated in recurrent tumors, whereas MGMT was upregulated. Recurrent tumor cells were found to be sensitive to treatment with an MGMT inhibitor and doxorubicin. These findings suggest that recurrence-specific targeting coupled with DNA repair inhibition comprises a potential therapeutic strategy in patients affected by medulloblastoma relapse.Significance: SOX9 facilitates therapy escape and recurrence in medulloblastoma via temporal inhibition of MYC/MYCN genes, revealing a strategy to specifically target SOX9-positive cells to prevent tumor relapse.

    Download full text (pdf)
    fulltext
  • 4.
    Doulabi, Ehsan Manouchehri
    et al.
    Uppsala University, Science for Life Laboratory, SciLifeLab. Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology.
    Fredolini, Claudia
    Uppsala University, Science for Life Laboratory, SciLifeLab. Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology.
    Gallini, Radiosa
    Uppsala University, Science for Life Laboratory, SciLifeLab. Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology, Molecular Tools and Functional Genomics.
    Löf, Liza
    Uppsala University, Science for Life Laboratory, SciLifeLab. Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology, Molecular Tools and Functional Genomics.
    Shen, Qiujin
    Uppsala University, Science for Life Laboratory, SciLifeLab. Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology, Molecular Tools and Functional Genomics.
    Ikebuchi, Ryoyo
    Uppsala University, Science for Life Laboratory, SciLifeLab. Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology, Molecular Tools and Functional Genomics. JSPS Overseas Research Fellow, Japan Society for the Promotion of Science, Tokyo, Japan.
    Dubois, Louise
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Medical Sciences, Clinical Chemistry.
    Azimi, Alireza
    Uppsala University, Science for Life Laboratory, SciLifeLab. Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology.
    Loudig, Olivier
    Center for Discovery and Innovation, Hackensack Meridian Health, Nutley, NJ, USA..
    Gabrielsson, Susanne
    Division of Immunology and Allergy, Department of Medicine, Karolinska Institutet, Solna, Sweden..
    Landegren, Ulf
    Uppsala University, Science for Life Laboratory, SciLifeLab. Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology, Molecular Tools and Functional Genomics.
    Larsson, Anders
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Medical Sciences, Clinical Chemistry.
    Bergquist, Jonas
    Uppsala University, Disciplinary Domain of Science and Technology, Chemistry, Department of Chemistry - BMC, Analytical Chemistry.
    Kamali-Moghaddam, Masood
    Uppsala University, Science for Life Laboratory, SciLifeLab. Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology, Molecular Tools and Functional Genomics.
    Surface protein profiling of prostate-derived extracellular vesicles by mass spectrometry and proximity assays2022In: Communications Biology, E-ISSN 2399-3642, Vol. 5, no 1, article id 1402Article in journal (Refereed)
    Abstract [en]

    Extracellular vesicles (EVs) are mediators of intercellular communication and a promising class of biomarkers. Surface proteins of EVs play decisive roles in establishing a connection with recipient cells, and they are putative targets for diagnostic assays. Analysis of the surface proteins can thus both illuminate the biological functions of EVs and help identify potential biomarkers. We developed a strategy combining high-resolution mass spectrometry (HRMS) and  proximity ligation assays (PLA) to first identify and then validate surface proteins discovered on EVs. We applied our workflow to investigate surface proteins of small EVs found in seminal fluid (SF-sEV). We identified 1,014 surface proteins and verified the presence of a subset of these on the surface of SF-sEVs. Our work demonstrates a general strategy for deep analysis of EVs' surface proteins across patients and pathological conditions, proceeding from unbiased screening by HRMS to ultra-sensitive targeted analyses via PLA.

    Download full text (pdf)
    fulltext
  • 5.
    Du, Qian
    et al.
    Northwest A&F Univ, Coll Vet Med, Yangling, Peoples R China.;Minist Educ, Engn Res Ctr Efficient New Vaccines Anim, Yangling, Peoples R China.;Minist Agr & Rural Affairs, Key Lab Ruminant Dis Prevent & Control West, Yangling, Peoples R China.;Univ Shaanxi Prov, Engn Res Ctr Efficient New Vaccines Anim, Yangling, Peoples R China..
    Zhu, Lei
    Northwest A&F Univ, Coll Vet Med, Yangling, Peoples R China..
    Zhong, Jianhui
    Northwest A&F Univ, Coll Vet Med, Yangling, Peoples R China..
    Wei, Xueqi
    Northwest A&F Univ, Coll Vet Med, Yangling, Peoples R China..
    Zhang, Qi
    Northwest A&F Univ, Coll Vet Med, Yangling, Peoples R China..
    Shi, Tengfei
    Northwest A&F Univ, Coll Vet Med, Yangling, Peoples R China..
    Han, Cong
    Northwest A&F Univ, Coll Vet Med, Yangling, Peoples R China..
    Yin, Xinhuan
    Northwest A&F Univ, Coll Vet Med, Yangling, Peoples R China..
    Chen, Xingqi
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology, Molecular Tools and Functional Genomics.
    Tong, Dewen
    Northwest A&F Univ, Coll Vet Med, Yangling, Peoples R China.;Minist Educ, Engn Res Ctr Efficient New Vaccines Anim, Yangling, Peoples R China.;Minist Agr & Rural Affairs, Key Lab Ruminant Dis Prevent & Control West, Yangling, Peoples R China.;Univ Shaanxi Prov, Engn Res Ctr Efficient New Vaccines Anim, Yangling, Peoples R China..
    Huang, Yong
    Northwest A&F Univ, Coll Vet Med, Yangling, Peoples R China.;Minist Educ, Engn Res Ctr Efficient New Vaccines Anim, Yangling, Peoples R China.;Minist Agr & Rural Affairs, Key Lab Ruminant Dis Prevent & Control West, Yangling, Peoples R China.;Univ Shaanxi Prov, Engn Res Ctr Efficient New Vaccines Anim, Yangling, Peoples R China..
    Porcine circovirus type 2 infection promotes the SUMOylation of nucleophosmin-1 to facilitate the viral circular single-stranded DNA replication2024In: PLoS Pathogens, ISSN 1553-7366, E-ISSN 1553-7374, Vol. 20, no 2, article id e1012014Article in journal (Refereed)
    Abstract [en]

    The mechanism of genome DNA replication in circular single-stranded DNA viruses is currently a mystery, except for the fact that it undergoes rolling-circle replication. Herein, we identified SUMOylated porcine nucleophosmin-1 (pNPM1), which is previously reported to be an interacting protein of the viral capsid protein, as a key regulator that promotes the genome DNA replication of porcine single-stranded DNA circovirus. Upon porcine circovirus type 2 (PCV2) infection, SUMO2/3 were recruited and conjugated with the K263 site of pNPM1's C-terminal domain to SUMOylate pNPM1, subsequently, the SUMOylated pNPM1 were translocated in nucleoli to promote the replication of PCV2 genome DNA. The mutation of the K263 site reduced the SUMOylation levels of pNPM1 and the nucleolar localization of pNPM1, resulting in a decrease in the level of PCV2 DNA replication. Meanwhile, the mutation of the K263 site prevented the interaction of pNPM1 with PCV2 DNA, but not the interaction of pNPM1 with PCV2 Cap. Mechanistically, PCV2 infection increased the expression levels of Ubc9, the only E2 enzyme involved in SUMOylation, through the Cap-mediated activation of ERK signaling. The upregulation of Ubc9 promoted the interaction between pNPM1 and TRIM24, a potential E3 ligase for SUMOylation, thereby facilitating the SUMOylation of pNPM1. The inhibition of ERK activation could significantly reduce the SUMOylation levels and the nucleolar localization of pNPM1, as well as the PCV2 DNA replication levels. These results provide new insights into the mechanism of circular single-stranded DNA virus replication and highlight NPM1 as a potential target for inhibiting PCV2 replication. Different types of DNA viruses employ different mechanisms to replicate their genome DNA. Porcine circovirus type 2 (PCV2) is the most representative circular single-stranded DNA virus that harms the pig industry all over the world. In this study, we found that the PCV2 Cap interacting protein pNPM1 also interacts with PCV2 DNA in a SUMOylated form to promote PCV2 DNA replication. The SUMOylation of pNPM1 at the conserved K263 site is critical for the interaction of pNPM1 with PCV2 DNA and the replication of PCV2 DNA. Furthermore, we found that PCV2 infection promotes the SUMO2/3 mediated SUMOylation of pNPM1, while does not significantly alter the expression level of pNPM1. PCV2 Cap is the major component that promotes pNPM1 SUMOylation by activating ERK/Ubc9/TRIM24 signalings. These results contribute to a better understanding of the replication mechanism of circular single-stranded DNA viruses, particularly PCV2.

    Download full text (pdf)
    FULLTEXT01
  • 6.
    Gillnäs, Sara
    et al.
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology.
    Gallini, Radiosa
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology, Molecular Tools and Functional Genomics.
    He, Liqun
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology, Vascular Biology.
    Betsholtz, Christer
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology, Vascular Biology.
    Andrae, Johanna
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology, Vascular Biology.
    Severe cerebellar malformations in mutant mice demonstrate a role for PDGF-C/PDGFR alpha signalling in cerebellar development2022In: BIOLOGY OPEN, ISSN 2046-6390, Vol. 11, no 8, article id bio059431Article in journal (Refereed)
    Abstract [en]

    Formation of the mouse cerebellum is initiated in the embryo and continues for a few weeks after birth. Double-mutant mice lacking platelet-derived growth factor C (PDGF-C) and that are heterozygous for platelet-derived growth factor receptor alpha (Pdgfc(-/-); Pdgfra(GFP/+)) develop cerebellar hypoplasia and malformation with loss of cerebellar lobes in the posterior vermis. This phenotype is similar to those observed in Foxc1 mutant mice and in a human neuroimaging pattern called Dandy Walker malformation. Pdgfc-Pdgfra mutant mice also display ependymal denudation in the fourth ventricle and gene expression changes in cerebellar meninges, which coincide with the first visible signs of cerebellar malformation. Here, we show that PDGF-C/PDGFR alpha signalling is a critical component in the network of molecular and cellular interactions that take place between the developing meninges and neural tissues, and which are required to build a fully functioning cerebellum.

    Download full text (pdf)
    fulltext
  • 7.
    Habicher, Judith
    et al.
    Uppsala University, Disciplinary Domain of Science and Technology, Biology, Department of Organismal Biology, Evolution and Developmental Biology. Department of Cellular, Computational and Integrative Biology (CIBIO), University of Trento, Trento, Italy.
    Varshney, Gaurav K.
    Genes & Human Disease Research Program, Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, United States of America .
    Waldmann, Laura
    Uppsala University, Disciplinary Domain of Science and Technology, Biology, Department of Organismal Biology, Evolution and Developmental Biology.
    Snitting, Daniel
    Uppsala University, Disciplinary Domain of Science and Technology, Biology, Department of Organismal Biology, Evolution and Developmental Biology.
    Allalou, Amin
    Uppsala University, Science for Life Laboratory, SciLifeLab. Uppsala University, Disciplinary Domain of Science and Technology, Mathematics and Computer Science, Department of Information Technology, Computerized Image Analysis and Human-Computer Interaction.
    Zhang, Hanqing
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology, Molecular Tools and Functional Genomics.
    Ghanem, Abdurrahman
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Medical Biochemistry and Microbiology.
    Öhman, Caroline
    Uppsala University, Disciplinary Domain of Science and Technology, Technology, Department of Materials Science and Engineering, Applied Material Science.
    Dierker, Tabea
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Medical Biochemistry and Microbiology.
    Kjellén, Lena
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Medical Biochemistry and Microbiology.
    Burgess, Shawn M.
    Translational and Functional Genomics Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland, United States of America .
    Ledin, Johan
    Uppsala University, Disciplinary Domain of Science and Technology, Biology, Department of Organismal Biology.
    Chondroitin/dermatan sulfate glycosyltransferase genes are essential for craniofacial development2022In: PLOS Genetics, ISSN 1553-7390, E-ISSN 1553-7404, Vol. 18, no 2, article id e1010067Article in journal (Refereed)
    Abstract [en]

    Chondroitin/dermatan sulfate (CS/DS) proteoglycans are indispensable for animal development and homeostasis but the large number of enzymes involved in their biosynthesis have made CS/DS function a challenging problem to study genetically. In our study, we generated loss-of-function alleles in zebrafish genes encoding CS/DS biosynthetic enzymes and characterized the effect on development in single and double mutants. Homozygous mutants in chsy1, csgalnact1a, csgalnat2, chpfa, ust and chst7, respectively, develop to adults. However, csgalnact1a-/- fish develop distinct craniofacial defects while the chsy1-/- skeletal phenotype is milder and the remaining mutants display no gross morphological abnormalities. These results suggest a high redundancy for the CS/DS biosynthetic enzymes and to further reduce CS/DS biosynthesis we combined mutant alleles. The craniofacial phenotype is further enhanced in csgalnact1a-/-;chsy1-/- adults and csgalnact1a-/-;csgalnact2-/- larvae. While csgalnact1a-/-;csgalnact2-/- was the most affected allele combination in our study, CS/DS is still not completely abolished. Transcriptome analysis of chsy1-/-, csgalnact1a-/- and csgalnact1a-/-;csgalnact2-/- larvae revealed that the expression had changed in a similar way in the three mutant lines but no differential expression was found in any of fifty GAG biosynthesis enzymes identified. Thus, zebrafish larvae do not increase transcription of GAG biosynthesis genes as a consequence of decreased CS/DS biosynthesis. The new zebrafish lines develop phenotypes similar to clinical characteristics of several human congenital disorders making the mutants potentially useful to study disease mechanisms and treatment.

    Download full text (pdf)
    fulltext
  • 8. Jamialahmadi, Oveis
    et al.
    Mujica, Endrina
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology, Molecular Tools and Functional Genomics. Uppsala University, Science for Life Laboratory, SciLifeLab.
    Mancina, Rosellina Margherita
    Ciociola, Ester
    Qadri, Sami F
    Maurotti, Samantha
    Malvestiti, Francesco
    Li-Gao, Ruifang
    Ronzoni, Luisa
    Tavaglione, Federica
    Allalou, Amin
    Uppsala University, Disciplinary Domain of Science and Technology, Mathematics and Computer Science, Department of Information Technology.
    Emmanouilidou, Anastasia
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology, Molecular Tools and Functional Genomics. Uppsala University, Science for Life Laboratory, SciLifeLab.
    Vespasiani-Gentilucci, Umberto
    Rosendaal, Frits Richard
    Yki-Järvinen, Hannele
    Valenti, Luca
    den Hoed, Marcel
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology, Molecular Tools and Functional Genomics. Uppsala University, Science for Life Laboratory, SciLifeLab.
    Romeo, Stefano
    Genome-wide interaction study with BMI identifies CYP7A1 and GIPR as genetic modulators of steatotic liver diseaseManuscript (preprint) (Other academic)
  • 9.
    Jin, Zhe
    et al.
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Medical Cell Biology.
    Hammoud, Hayma
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Medical Cell Biology.
    Bhandage, Amol
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Medical Cell Biology.
    Korol, Sergiy Vasylyovych
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Medical Cell Biology.
    Trujeque-Ramos, Olivia
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Medical Cell Biology.
    Koreli, Stasini
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Medical Cell Biology.
    Gong, Zhitao
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Medical Cell Biology.
    Chowdhury, Azazul Islam
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Medical Cell Biology.
    Sandbaumhüter, Friederike Andrea
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Pharmacy, Department of Pharmaceutical Biosciences.
    Jansson, Erik Tomas
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Pharmacy, Department of Pharmaceutical Biosciences.
    Lindsay, Robin Sean
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Medical Cell Biology.
    Christoffersson, Gustaf
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Medical Cell Biology.
    Andrén, Per Erik
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Pharmacy, Department of Pharmaceutical Biosciences. Uppsala University, Science for Life Laboratory, SciLifeLab.
    Carlsson, Per-Ola
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Medical Cell Biology.
    Bergsten, Peter
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Medical Cell Biology.
    Kamali-Moghaddam, Masood
    Uppsala University, Science for Life Laboratory, SciLifeLab. Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology, Molecular Tools and Functional Genomics.
    Birnir, Bryndis
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Medical Cell Biology.
    GABA-mediated inhibition of human CD4+ T cell functions is enhanced by insulin but impaired by high glucose levels2024In: EBioMedicine, E-ISSN 2352-3964, Vol. 105, article id 105217Article in journal (Refereed)
    Abstract [en]

    BACKGROUND: γ-aminobutyric acid (GABA), known as the main inhibitory neurotransmitter in the brain, exerts immunomodulatory functions by interaction with immune cells, including T cells. Metabolic programs of T cells are closely linked to their effector functions including proliferation, differentiation, and cytokine production. The physiological molecules glucose and insulin may provide environmental cues and guidance, but whether they coordinate to regulate GABA-mediated T cell immunomodulation is still being examined.

    METHODS: CD4+ T cells that were isolated from blood samples from healthy individuals and from patients with type 1 diabetes (T1D) were activated in vitro. We carried out metabolic assays, multiple proximity extension assay (PEA), ELISA, qPCR, immunoblotting, immunofluorescence staining, flow cytometry analysis, MS-based proteomics, as well as electrophysiology and live-cell Ca2+ imaging.

    FINDINGS: We demonstrate that GABA-mediated reduction of metabolic activity and the release of inflammatory proteins, including IFNγ and IL-10, were abolished in human CD4+ T cells from healthy individuals and patients with T1D when the glucose concentration was elevated above levels typically observed in healthy people. Insulin increased GABAA receptor-subunit ρ2 expression, enhanced the GABAA receptors-mediated currents and Ca2+ influx. GABA decreased, whereas insulin sustained, hexokinase activity and glycolysis in a glucose concentration-dependent manner.

    INTERPRETATION: These findings support that metabolic factors, such as glucose and insulin, influence the GABA-mediated immunomodulation of human primary T cells effector functions.

    FUNDING: The Swedish Children's Diabetes Foundation, The Swedish Diabetes Foundation, The Swedish Research Council 2018-02952, EXODIAB, The Ernfors Foundation, The Thurings Foundation and the Science for Life Laboratory.

    Download full text (pdf)
    fulltext
  • 10.
    Kuenstner, Axel
    et al.
    Univ Lubeck, Med Syst Biol Grp, Ratzeburger Allee 160, D-23538 Lubeck, Germany.;Univ Hosp Schleswig Holstein, Univ Canc Ctr Schleswig Holstein, Campus Lubeck, D-23538 Lubeck, Germany..
    Schwarting, Julian
    Univ Hosp Schleswig Holstein, Univ Canc Ctr Schleswig Holstein, Campus Lubeck, D-23538 Lubeck, Germany.;Univ Hosp Schleswig Holstein, Dept Hematol & Oncol, Campus Lubeck,Ratzeburger Allee 160, D-23538 Lubeck, Germany.;Hamatopathol Lubeck, Consultat Ctr Lymph Node Pathol & Hematopathol, D-23562 Lubeck, Germany..
    Witte, Hanno M.
    Univ Hosp Schleswig Holstein, Univ Canc Ctr Schleswig Holstein, Campus Lubeck, D-23538 Lubeck, Germany.;Univ Hosp Schleswig Holstein, Dept Hematol & Oncol, Campus Lubeck,Ratzeburger Allee 160, D-23538 Lubeck, Germany.;Fed Armed Forces Hosp Ulm, Dept Hematol & Oncol, Oberer Eselsberg 40, D-89081 Ulm, Germany..
    Xing, Pengwei
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology, Molecular Tools and Functional Genomics.
    Bernard, Veronica
    Hamatopathol Lubeck, Consultat Ctr Lymph Node Pathol & Hematopathol, D-23562 Lubeck, Germany..
    Stoelting, Stephanie
    Hamatopathol Lubeck, Consultat Ctr Lymph Node Pathol & Hematopathol, D-23562 Lubeck, Germany..
    Lohneis, Philipp
    Hamatopathol Lubeck, Consultat Ctr Lymph Node Pathol & Hematopathol, D-23562 Lubeck, Germany..
    Janke, Florian
    German Canc Res Ctr, Div Canc Genome Res, D-69120 Heidelberg, Germany.;German Canc Consortium DKTK, D-69120 Heidelberg, Germany..
    Salehi, Maede
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology.
    Chen, Xingqi
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology, Molecular Tools and Functional Genomics.
    Kusch, Kathrin
    Hamatopathol Lubeck, Consultat Ctr Lymph Node Pathol & Hematopathol, D-23562 Lubeck, Germany..
    Sueltmann, Holger
    German Canc Res Ctr, Div Canc Genome Res, D-69120 Heidelberg, Germany.;German Canc Consortium DKTK, D-69120 Heidelberg, Germany..
    Chteinberg, Emil
    Ulm Univ, Inst Human Genet, Ulm, Germany.;Ulm Univ, Med Ctr, D-89081 Ulm, Germany..
    Fischer, Anja
    Ulm Univ, Inst Human Genet, Ulm, Germany.;Ulm Univ, Med Ctr, D-89081 Ulm, Germany..
    Siebert, Reiner
    Ulm Univ, Inst Human Genet, Ulm, Germany.;Ulm Univ, Med Ctr, D-89081 Ulm, Germany..
    von Bubnoff, Nikolas
    Univ Hosp Schleswig Holstein, Univ Canc Ctr Schleswig Holstein, Campus Lubeck, D-23538 Lubeck, Germany.;Univ Hosp Schleswig Holstein, Dept Hematol & Oncol, Campus Lubeck,Ratzeburger Allee 160, D-23538 Lubeck, Germany..
    Merz, Hartmut
    Hamatopathol Lubeck, Consultat Ctr Lymph Node Pathol & Hematopathol, D-23562 Lubeck, Germany..
    Busch, Hauke
    Univ Lubeck, Med Syst Biol Grp, Ratzeburger Allee 160, D-23538 Lubeck, Germany.;Univ Hosp Schleswig Holstein, Univ Canc Ctr Schleswig Holstein, Campus Lubeck, D-23538 Lubeck, Germany..
    Feller, Alfred C.
    Hamatopathol Lubeck, Consultat Ctr Lymph Node Pathol & Hematopathol, D-23562 Lubeck, Germany..
    Gebauer, Niklas
    Univ Hosp Schleswig Holstein, Univ Canc Ctr Schleswig Holstein, Campus Lubeck, D-23538 Lubeck, Germany.;Univ Hosp Schleswig Holstein, Dept Hematol & Oncol, Campus Lubeck,Ratzeburger Allee 160, D-23538 Lubeck, Germany..
    Genome-wide DNA methylation-analysis of blastic plasmacytoid dendritic cell neoplasm identifies distinct molecular features2024In: Leukemia, ISSN 0887-6924, E-ISSN 1476-5551, Vol. 38, no 5, p. 1086-1098Article in journal (Refereed)
    Abstract [en]

    Blastic plasmacytoid dendritic cell neoplasm (BPDCN) constitutes a rare and aggressive malignancy originating from plasmacytoid dendritic cells (pDCs) with a primarily cutaneous tropism followed by dissemination to the bone marrow and other organs. We conducted a genome-wide analysis of the tumor methylome in an extended cohort of 45 BPDCN patients supplemented by WES and RNA-seq as well as ATAC-seq on selected cases. We determined the BPDCN DNA methylation profile and observed a dramatic loss of DNA methylation during malignant transformation from early and mature DCs towards BPDCN. DNA methylation profiles further differentiate between BPDCN, AML, CMML, and T-ALL exhibiting the most striking global demethylation, mitotic stress, and merely localized DNA hypermethylation in BPDCN resulting in pronounced inactivation of tumor suppressor genes by comparison. DNA methylation-based analysis of the tumor microenvironment by MethylCIBERSORT yielded two, prognostically relevant clusters (IC1 and IC2) with specific cellular composition and mutational spectra. Further, the transcriptional subgroups of BPDCN (C1 and C2) differ by DNA methylation signatures in interleukin/inflammatory signaling genes but also by higher transcription factor activity of JAK-STAT and NFkB signaling in C2 in contrast to an EZH2 dependence in C1-BPDCN. Our integrative characterization of BPDCN offers novel molecular insights and potential diagnostic applications.

    Download full text (pdf)
    FULLTEXT01
  • 11.
    Landegren, Ulf
    Uppsala University, Science for Life Laboratory, SciLifeLab. Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology, Molecular Tools and Functional Genomics.
    Molecular tools to monitor health and disease - and lucky coincidences2022In: Upsala Journal of Medical Sciences, ISSN 0300-9734, E-ISSN 2000-1967, Vol. 127, no 1, article id e8987Article, review/survey (Refereed)
    Abstract [en]

    Improved methods for molecular analyses are obviously central for medical research. I will describe herein our work developing tools to reveal molecular states in health and disease. I will recount how I got started in this endeavor, and how our early work characterizing genetic variation led onto high-throughput protein measurements and to techniques for imaging the distribution of proteins and their activity states in tissues. I will also describe a more recent technique to measure even exceedingly rare genetic variants in order to monitor recurrence of disease for tumor patients.

    Download full text (pdf)
    FULLTEXT01
  • 12.
    LAURENT, EMILIE
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology, Molecular Tools and Functional Genomics. Uppsala University, Disciplinary Domain of Science and Technology, Biology, Biology Education Centre.
    Understanding the chromatin regulatory variation with single cell ATAC sequencing2020Independent thesis Advanced level (degree of Master (Two Years)), 20 credits / 30 HE creditsStudent thesis
  • 13.
    Li, Chen
    et al.
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Medical Biochemistry and Microbiology. Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Medical Sciences, Dermatology and Venereology.
    Sun, Chengxi
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Medical Biochemistry and Microbiology. Department of Clinical Laboratory, Cheeloo College of Medicine, Shandong University, 250012, Jinan, Shandong, China.
    Lohcharoenkal, Warangkana
    Ali, Mohamad Moustafa
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Medical Biochemistry and Microbiology.
    Xing, Pengwei
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology, Molecular Tools and Functional Genomics.
    Zheng, Wenyi
    Görgens, André
    Gustafsson, Manuela O.
    EL Andaloussi, Samir
    Sonkoly, Enikö
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Medical Sciences, Dermatology and Venereology. Unit of Dermatology and Venerology, Department of Medicine, Karolinska Institutet, Stockholm, SE, 17176, Sweden.
    Pivarcsi, Andor
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Medical Biochemistry and Microbiology. Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Medical Sciences, Dermatology and Venereology. Unit of Dermatology and Venerology, Department of Medicine, Karolinska Institutet, Stockholm, SE, 17176, Sweden.
    Cutaneous squamous cell carcinoma-derived extracellular vesicles exert an oncogenic role by activating cancer-associated fibroblasts2023In: Cell Death Discovery, E-ISSN 2058-7716, Vol. 9, no 1, article id 260Article in journal (Refereed)
    Abstract [en]

    Cutaneous squamous cell carcinoma (cSCC) is a fast-increasing cancer with metastatic potential. Extracellular vesicles (EVs) are small membrane-bound vesicles that play important roles in intercellular communication, particularly in the tumor microenvironment (TME). Here we report that cSCC cells secrete an increased number of EVs relative to normal human epidermal keratinocytes (NHEKs) and that interfering with the capacity of cSCC to secrete EVs inhibits tumor growth in vivo in a xenograft model of human cSCC. Transcriptome analysis of tumor xenografts by RNA-sequencing enabling the simultaneous quantification of both the human and the mouse transcripts revealed that impaired EV-production of cSCC cells prominently altered the phenotype of stromal cells, in particular genes related to extracellular matrix (ECM)-formation and epithelial-mesenchymal transition (EMT). In line with these results, co-culturing of human dermal fibroblasts (HDFs) with cSCC cells, but not with normal keratinocytes in vitro resulted in acquisition of cancer-associated fibroblast (CAF) phenotype. Interestingly, EVs derived from metastatic cSCC cells, but not primary cSCCs or NHEKs, were efficient in converting HDFs to CAFs. Multiplex bead-based flow cytometry assay and mass-spectrometry (MS)-based proteomic analyses revealed the heterogenous cargo of cSCC-derived EVs and that especially EVs derived from metastatic cSCCs carry proteins associated with EV-biogenesis, EMT, and cell migration. Mechanistically, EVs from metastatic cSCC cells result in the activation of TGFβ signaling in HDFs. Altogether, our study suggests that cSCC-derived EVs mediate cancer-stroma communication, in particular the conversion of fibroblasts to CAFs, which eventually contribute to cSCC progression.

    Download full text (pdf)
    fulltext
  • 14.
    Li, Honglian
    et al.
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Medical Biochemistry and Microbiology. Uppsala University, Science for Life Laboratory, SciLifeLab.
    Zhang, Hua
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology.
    Wenz, Amelie S.
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology.
    Kang, Ziqi
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology.
    Wang, Helen
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Medical Biochemistry and Microbiology. Uppsala University, Science for Life Laboratory, SciLifeLab.
    Vlodavsky, Israel
    Technion, Technion Integrated Canc Ctr TICC, Rappaport Fac Med, IL-31096 Haifa, Israel..
    Chen, Xingqi
    Uppsala University, Science for Life Laboratory, SciLifeLab. Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology, Molecular Tools and Functional Genomics.
    Li, Jin-Ping
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Medical Biochemistry and Microbiology. Uppsala University, Science for Life Laboratory, SciLifeLab.
    Heparanase Modulates Chromatin Accessibility2023In: Cells, E-ISSN 2073-4409, Vol. 12, no 6, article id 891Article in journal (Refereed)
    Abstract [en]

    Heparanase is the sole endoglucuronidase that degrades heparan sulfate in the cell surface and extracellular matrix (ECM). Several studies have reported the localization of heparanase in the cell nucleus, but the functional role of the nuclear enzyme is still obscure. Subjecting mouse embryonic fibroblasts (MEFs) derived from heparanase knockout (Hpse-KO) mice and applying transposase-accessible chromatin with sequencing (ATAC-seq), we revealed that heparanase is involved in the regulation of chromatin accessibility. Integrating with genome-wide analysis of chromatin states revealed an overall low activity in the enhancer and promoter regions of Hpse-KO MEFs compared with wild-type (WT) MEFs. Western blot analysis of MEFs and tissues derived from Hpse-KO vs. WT mice confirmed reduced expression of H3K27ac (acetylated lysine at N-terminal position 27 of the histone H3 protein). Our results offer a mechanistic explanation for the well-documented attenuation of inflammatory responses and tumor growth in Hpse-KO mice.

    Download full text (pdf)
    FULLTEXT01
  • 15.
    Lu, Xi
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology, Molecular Tools and Functional Genomics.
    Integrative Modeling of Epigenetic Regulation in Human Disease2023Doctoral thesis, comprehensive summary (Other academic)
    Abstract [en]

    Glioblastoma is the most common and aggressive primary brain tumor. Standard of treatment prove ineffective, leading to tumor recurrence and an average survival rate of 14 months. This treatment resistance is attributed to both inter-tumor and intra-tumor heterogeneity observed across diverse tumor samples and within individual cells. Dravet syndrome is a severe early-onset refractory epilepsy characterized by an unfavorable long-term outcome and medication resistance. In this thesis, patient-derived stem cell culture models were utilized to study both diseases. We employed sequencing technologies, including the Assay for Transposase-Accessible Chromatin with high-throughput sequencing and single-cell multi-omics technologies to delve into cell-lineage-controlled epigenetic regulation in glioblastoma, the mechanism behind the recurrence of glioblastoma and epigenetic dysfunction in Dravet syndrome patients during neural development. 

    In Paper I, we validated the impacts of the developmental origin on human glioblastoma stem cell groups and revealed conserved epigenetic regulation between mouse and human glioblastoma stem cells through cross-species epigenome analysis. Human glioblastoma stem cell clusters exhibited distinct functional properties and have significant clinical outcomes. 

    In Paper II, we discovered that the infiltrative region of the primary bulk tumor was more invasive and less self-renewing and tumorigenic compared to its paired bulk culture. Single-cell multi-omics sequencing showed an inclination towards astrocyte-like/mesenchymal-like cell states in edge cultures across all patients from transcriptomic aspect and chromatin-accessibility profiles highlighting edge cells associated with cell invasion, inflammation, and myeloid cells. 

    In Paper III, we offered critical insights into the dysfunction of regulatory chromatin in Dravet syndrome patients using time-series ATAC sequencing. We observed that heathy individuals and Dravet syndrome patients were regulated by different transcription factors during development. Treatment with VPA effectively reshaped the chromatin landscape and rescued the observed dysfunctional development in some Dravet syndrome patients.

    List of papers
    1. Cell-lineage controlled epigenetic regulation in glioblastoma stem cells determines functionally distinct subgroups and predicts patient survival
    Open this publication in new window or tab >>Cell-lineage controlled epigenetic regulation in glioblastoma stem cells determines functionally distinct subgroups and predicts patient survival
    Show others...
    2022 (English)In: Nature Communications, E-ISSN 2041-1723, Vol. 13, article id 2236Article in journal (Refereed) Published
    Abstract [en]

    The epigenetic regulation of glioblastoma stem cell (GSC) function remains poorly understood. Here, the authors compare the chromatin accessibility landscape of GSC cultures from mice and patients and suggest that the epigenome of GSCs is cell lineage-regulated and could predict patient survival. There is ample support for developmental regulation of glioblastoma stem cells. To examine how cell lineage controls glioblastoma stem cell function, we present a cross-species epigenome analysis of mouse and human glioblastoma stem cells. We analyze and compare the chromatin-accessibility landscape of nine mouse glioblastoma stem cell cultures of three defined origins and 60 patient-derived glioblastoma stem cell cultures by assay for transposase-accessible chromatin using sequencing. This separates the mouse cultures according to cell of origin and identifies three human glioblastoma stem cell clusters that show overlapping characteristics with each of the mouse groups, and a distribution along an axis of proneural to mesenchymal phenotypes. The epigenetic-based human glioblastoma stem cell clusters display distinct functional properties and can separate patient survival. Cross-species analyses reveals conserved epigenetic regulation of mouse and human glioblastoma stem cells. We conclude that epigenetic control of glioblastoma stem cells primarily is dictated by developmental origin which impacts clinically relevant glioblastoma stem cell properties and patient survival.

    Place, publisher, year, edition, pages
    Springer NatureSpringer Nature, 2022
    National Category
    Cancer and Oncology
    Identifiers
    urn:nbn:se:uu:diva-474702 (URN)10.1038/s41467-022-29912-2 (DOI)000787388900011 ()35469026 (PubMedID)
    Funder
    Swedish Research Council, 2016-06794Swedish Research Council, 2017-02074Swedish Research Council, 2018-02906Knut and Alice Wallenberg FoundationSwedish Cancer Society, 15 0877Swedish Cancer Society, 18 0763Swedish Cancer Society, 21 1518Swedish Cancer Society, 21 1449Swedish Cancer Society, 22 0491 JIAHedlund foundationScience for Life Laboratory, SciLifeLabKjell and Marta Beijer FoundationHarald and Greta Jeansson FoundationGöran Gustafsson Foundation for promotion of scientific research at Uppala University and Royal Institute of TechnologyÅke Wiberg Foundation
    Note

    De två första författarna delar förstaförfattarskapet.

    De två sista författarna delar sistaförfattarskapet.

    Available from: 2022-05-25 Created: 2022-05-25 Last updated: 2024-01-15Bibliographically approved
    2. Paired glioblastoma cell cultures of the fluorescent bulk tumor and non-fluorescent tumor margin display differential phenotypes and cell states across patients
    Open this publication in new window or tab >>Paired glioblastoma cell cultures of the fluorescent bulk tumor and non-fluorescent tumor margin display differential phenotypes and cell states across patients
    Show others...
    (English)Manuscript (preprint) (Other academic)
    Abstract [en]

    Glioblastoma is an aggressive and therapy-resistant primary brain tumor with a dismal prognosis. The inevitable recurrence is in almost all patients in contact with the resection cavity, suggesting the local peritumoral area as its origin. Glioblastoma cells of this region have seldom been studied and few authenticated models exist. We have explanted matched tissue samples from the bulk tumor and local tumor edge of 13 glioblastoma patients of which 7 were sustainable beyond passage 6. Each edge culture was more invasive and less self-renewing and tumorigenic compared to its paired bulk culture. Three pairs of edge and bulk cultures were profiled with a combined single nucleus (sn) RNA- and ATAC-sequencing. Transcriptome analysis displayed for all patients a shift towards AC-MES cell states in the edge cultures. Chromatin-accessibility profiles uncovered differential regulatory networks with edge cells being enriched for transcription factor (TF) motifs of invasion, neurons, and immune cells. We propose that edge cells have been epigenetically reprogrammed by their unique interactions with various cell types in the peritumoral region. The fact that glioblastoma edge cells display distinct epigenetic regulation compared to their bulk tumor cells has implications for therapy development that should be targeted to and tested on the relapse-causing glioblastoma edge cells.

    National Category
    Medical Genetics
    Identifiers
    urn:nbn:se:uu:diva-512539 (URN)
    Available from: 2023-09-27 Created: 2023-09-27 Last updated: 2023-09-27
    3. Epigenetic insights into GABAergic development in Dravet Syndrome iPSC and therapeutic implications
    Open this publication in new window or tab >>Epigenetic insights into GABAergic development in Dravet Syndrome iPSC and therapeutic implications
    Show others...
    2024 (English)In: eLIFE, E-ISSN 2050-084X, Vol. 12, article id RP92599Article in journal (Refereed) Published
    Abstract [en]

    Dravet syndrome (DS) is a devastating early-onset refractory epilepsy syndrome caused by variants in the SCN1A gene. A disturbed GABAergic interneuron function is implicated in the progression to DS but the underlying developmental and pathophysiological mechanisms remain elusive, in particularly at the chromatin level. Induced pluripotent stem cells (iPSCs) derived from DS cases and healthy donors were used to model disease-associated epigenetic abnormalities of GABAergic development. Chromatin accessibility was assessed at multiple time points (Day 0, Day 19, Day 35, and Day 65) of GABAergic differentiation. Additionally, the effects of the commonly used anti-seizure drug valproic acid (VPA) on chromatin accessibility were elucidated in GABAergic cells. The distinct dynamics in the chromatin profile of DS iPSC predicted accelerated early GABAergic development, evident at D19, and diverged further from the pattern in control iPSC with continued differentiation, indicating a disrupted GABAergic maturation. Exposure to VPA at D65 reshaped the chromatin landscape at a variable extent in different iPSC-lines and rescued the observed dysfunctional development of some DS iPSC-GABA. The comprehensive investigation on the chromatin landscape of GABAergic differentiation in DS-patient iPSC offers valuable insights into the epigenetic dysregulations associated with interneuronal dysfunction in DS. Moreover, the detailed analysis of the chromatin changes induced by VPA in iPSC-GABA holds the potential to improve the development of personalized and targeted anti-epileptic therapies.

    Place, publisher, year, edition, pages
    eLife Sciences Publications Ltd, 2024
    National Category
    Medical Genetics
    Identifiers
    urn:nbn:se:uu:diva-512540 (URN)10.7554/eLife.92599 (DOI)001300332500001 ()39190448 (PubMedID)
    Funder
    Swedish Research Council, 2022-00658Swedish Research Council, 2020-01947The Swedish Brain Foundation, FO2020-0171The Swedish Brain Foundation, FO2022-0042Swedish Cancer Society, 212119PjSwedish Cancer Society, 220491Knut and Alice Wallenberg Foundation, 2023.0046Föreningen MargaretahemmetStiftelsen SävstaholmUppsala UniversityScience for Life Laboratory, SciLifeLab
    Note

    De tre första författarna delar förstaförfattarskapet

    Available from: 2023-09-26 Created: 2023-09-26 Last updated: 2024-09-12Bibliographically approved
    Download full text (pdf)
    UUThesis_X-Lu-2023
    Download (jpg)
    preview image
  • 16.
    Lu, Xi
    et al.
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology, Neurooncology and neurodegeneration.
    Zhong, Lei
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology, Cancer precision medicine. Department of Pharmacy, Personalized Drug Therapy Key Laboratory of Sichuan Province, Sichuan Provincial People’s Hospital, Sichuan, China.
    Lindell, Emma
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology, Cancer precision medicine.
    Veanes, Margus
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology, Cancer precision medicine.
    Guo, Jing
    Centre for Computational Biology, Duke-NUS Medical School, 8 College Road, 169857, Singapore, Singapore.
    Zhao, Miao
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology, Neurooncology and neurodegeneration.
    Salehi, Maede
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology.
    Swartling, Fredrik J.
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology, Neurooncology and neurodegeneration.
    Chen, Xingqi
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology, Molecular Tools and Functional Genomics.
    Sjöblom, Tobias
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology, Cancer precision medicine.
    Zhang, Xiaonan
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology, Cancer precision medicine.
    Identification of ATF3 as a novel protective signature of quiescent colorectal tumor cells2023In: Cell Death and Disease, E-ISSN 2041-4889, Vol. 14, no 10, article id 676Article in journal (Refereed)
    Abstract [en]

    Colorectal cancer (CRC) is the third most common cancer and the second leading cause of death in the world. In most cases, drug resistance and tumor recurrence are ultimately inevitable. One obstacle is the presence of chemotherapy-insensitive quiescent cancer cells (QCCs). Identification of unique features of QCCs may facilitate the development of new targeted therapeutic strategies to eliminate tumor cells and thereby delay tumor recurrence. Here, using single-cell RNA sequencing, we classified proliferating and quiescent cancer cell populations in the human colorectal cancer spheroid model and identified ATF3 as a novel signature of QCCs that could support cells living in a metabolically restricted microenvironment. RNA velocity further showed a shift from the QCC group to the PCC group indicating the regenerative capacity of the QCCs. Our further results of epigenetic analysis, STING analysis, and evaluation of TCGA COAD datasets build a conclusion that ATF3 can interact with DDIT4 and TRIB3 at the transcriptional level. In addition, decreasing the expression level of ATF3 could enhance the efficacy of 5-FU on CRC MCTS models. In conclusion, ATF3 was identified as a novel marker of QCCs, and combining conventional drugs targeting PCCs with an option to target QCCs by reducing ATF3 expression levels may be a promising strategy for more efficient removal of tumor cells.

    Download full text (pdf)
    fulltext
  • 17.
    Maaninka, Katariina
    et al.
    Univ Helsinki, Fac Biol & Environm Sci, Mol & Integrat Biosci Res Programme, EV Grp, Helsinki, Finland.;Univ Helsinki, Fac Pharm, Drug Res Program, Div Pharmaceut Biosci,CURED, Helsinki, Finland.;Univ Helsinki, Fac Biol & Environm Sci, Mol & Integrat Biosci Res Programme, EV Core, Helsinki, Finland..
    Neuvonen, Maarit
    Univ Helsinki, Fac Biol & Environm Sci, Mol & Integrat Biosci Res Programme, EV Grp, Helsinki, Finland.;Univ Helsinki, Fac Pharm, Drug Res Program, Div Pharmaceut Biosci,CURED, Helsinki, Finland..
    Kerkelä, Erja
    Finnish Red Cross Blood Serv FRCBS, Helsinki, Finland..
    Hyvärinen, Kati
    Finnish Red Cross Blood Serv FRCBS, Helsinki, Finland..
    Palviainen, Mari
    Univ Helsinki, Fac Biol & Environm Sci, Mol & Integrat Biosci Res Programme, EV Grp, Helsinki, Finland.;Univ Helsinki, Fac Pharm, Drug Res Program, Div Pharmaceut Biosci,CURED, Helsinki, Finland.;Univ Helsinki, Fac Biol & Environm Sci, Mol & Integrat Biosci Res Programme, EV Core, Helsinki, Finland..
    Kamali-Moghaddam, Masood
    Uppsala University, Science for Life Laboratory, SciLifeLab. Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology, Molecular Tools and Functional Genomics.
    Federico, Antonio
    Tampere Univ, Fac Med & Hlth Technol, Finnish Hub Dev & Validat Integrated Approaches F, Tampere, Finland..
    Greco, Dario
    Tampere Univ, Fac Med & Hlth Technol, Finnish Hub Dev & Validat Integrated Approaches F, Tampere, Finland.;Univ Helsinki, Fac Pharm, Div Pharmaceut Biosci, Helsinki, Finland..
    Laitinen, Saara
    Finnish Red Cross Blood Serv FRCBS, Helsinki, Finland..
    Öörni, Katariina
    Wihuri Res Inst, Atherosclerosis Res Lab, Helsinki, Finland..
    Siljander, Pia R. M.
    Univ Helsinki, Fac Biol & Environm Sci, Mol & Integrat Biosci Res Programme, EV Grp, Helsinki, Finland.;Univ Helsinki, Fac Pharm, Drug Res Program, Div Pharmaceut Biosci,CURED, Helsinki, Finland.;Univ Helsinki, Fac Biol & Environm Sci, Mol & Integrat Biosci Res Programme, EV Core, Helsinki, Finland..
    OxLDL sensitizes platelets for increased formation of extracellular vesicles capable of finetuning macrophage gene expression2023In: European Journal of Cell Biology, ISSN 0171-9335, E-ISSN 1618-1298, Vol. 102, no 2, article id 151311Article in journal (Refereed)
    Abstract [en]

    Platelet extracellular vesicles (PEVs) generated upon platelet activation may play a role in inflammatory pathologies such as atherosclerosis. Oxidized low-density lipoprotein (oxLDL), a well-known contributor to atherogenesis, activates platelets and presensitizes them for activation by other agonists. We studied the effect of oxLDL on the secretion, composition, and inflammatory functions of PEVs using contemporary EV analytics. Platelets were activated by co-stimulation with thrombin (T) and collagen (C) ± oxLDL and characterized by high-resolution flow cytometry, nanoparticle tracking analysis, proximity extension assay, western blot, and electron microscopy. The effect of PEVs on macrophage differentiation and functionality was examined by analyzing macrophage surface markers, cytokine secretion, and transcriptome. OxLDL upregulated TC-induced formation of CD61+, P-selectin+ and phosphatidylserine+ PEVs. Blocking the scavenger receptor CD36 significantly suppressed the oxLDL+TC-induced PEV formation, and HDL caused a slight but detectable suppression. The inflammatory protein cargo differed between the PEVs from stimulated and unstimulated platelets. Both oxLDL+TC- and TC-induced PEVs enhanced macrophage HLA-DR and CD86 expression and decreased CD11c expression as well as secretion of several cytokines. Pathways related to cell cycle and regulation of gene expression, and immune system signaling were overrepresented in the differentially expressed genes between TC PEV -treated vs. control macrophages and oxLDL+TC PEV -treated vs. control macrophages, respectively. In conclusion, we speculate that oxLDL and activated platelets contribute to proatherogenic processes by increasing the number of PEVs that provide an adhesive and procoagulant surface, contain inflammatory mediators, and subtly finetune the macrophage gene expression.

    Download full text (pdf)
    fulltext
  • 18.
    Manouchehri Doulabi, Ehsan
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology, Molecular Tools and Functional Genomics.
    Molecular Tools for Detection and Characterization of Proteins and Extracellular Vesicles in Health and Disease2023Doctoral thesis, comprehensive summary (Other academic)
    Abstract [en]

    Detecting molecules involved in cancer is critical for cancer research and diagnostics. To achieve this goal, sensitive protein detection is essential to improving the chances of finding, verifying, validating and developing valuable biomarkers. Extracellular vesicles (EVs) are membrane-enclosed nanometer-size structures that can transport macromolecular information between cells. While they play an essential role in cell-to-cell communication, they may also prove important as biomarkers for minimally invasive detection of cancer. In this doctoral thesis the aim was to establish protocols for proteome analysis of EVs, specifically to identify combinations of surface proteins on the EVs by labeling surface proteins followed by protein identification via mass spectrometry. Also, using the proximity ligation and extension assays the challenges have been met of discovering and validating proteomics biomarkers with very low amounts of EVs. In paper I the aim was to develop a detection method and protocol combining high-resolution mass spectrometry with solid-phase- and Exo PLAs for identifying surface proteins on EVs with relevance in prostate cancer. The protocol allowed identification of more than 1,000 surface proteins, many not previously reported to be carried by EVs. In Paper II we used five protein assay panels consisting of more than 400 proteins to assess and analyze the proteomics profiles of EVs isolated from four different gastric cancer cell lines. The data identified 39 proteins with medium or high expression levels in EVs from gastric cancer cell lines, which were not expressed or are only present at low concentrations in control EVs from seminal fluid. In Paper III we analyzed and measured thymidine kinase 1 enzyme activity in EVs purified from seminal fluids from healthy individuals and from normal and prostate cancer cell lines. Thymidine kinase 1 is a cell cycle-dependent enzyme and a biomarker for cell proliferation. The results indicate a correlation of TK1 enzyme activates with the aggressiveness of the tumor cell lines and higher enzyme activity was recorded for EVs isolated from p53 null and mutated cell lines compared to cells with wild-type p53. Paper IV describes a high-throughput approach using in situ proximity ligation assays (in situ PLA) to investigate protein interactions and post-translational modifications in the HaCAT cell line. In situ PLA was combined with automated microscopy and computerized analysis to evaluate phosphorylation and protein interaction along with subcellular features in response to drug treatment. In summary, the focus of this Ph.D. thesis has been to adopt a variety of proteomic techniques for investigating EVs as biomarkers in health and disease. 

    List of papers
    1. Surface protein profiling of prostate-derived extracellular vesicles by mass spectrometry and proximity assays
    Open this publication in new window or tab >>Surface protein profiling of prostate-derived extracellular vesicles by mass spectrometry and proximity assays
    Show others...
    2022 (English)In: Communications Biology, E-ISSN 2399-3642, Vol. 5, no 1, article id 1402Article in journal (Refereed) Published
    Abstract [en]

    Extracellular vesicles (EVs) are mediators of intercellular communication and a promising class of biomarkers. Surface proteins of EVs play decisive roles in establishing a connection with recipient cells, and they are putative targets for diagnostic assays. Analysis of the surface proteins can thus both illuminate the biological functions of EVs and help identify potential biomarkers. We developed a strategy combining high-resolution mass spectrometry (HRMS) and  proximity ligation assays (PLA) to first identify and then validate surface proteins discovered on EVs. We applied our workflow to investigate surface proteins of small EVs found in seminal fluid (SF-sEV). We identified 1,014 surface proteins and verified the presence of a subset of these on the surface of SF-sEVs. Our work demonstrates a general strategy for deep analysis of EVs' surface proteins across patients and pathological conditions, proceeding from unbiased screening by HRMS to ultra-sensitive targeted analyses via PLA.

    Place, publisher, year, edition, pages
    Springer Nature, 2022
    National Category
    Urology and Nephrology
    Identifiers
    urn:nbn:se:uu:diva-491799 (URN)10.1038/s42003-022-04349-x (DOI)000903280800006 ()36550367 (PubMedID)
    Funder
    Uppsala University
    Available from: 2022-12-23 Created: 2022-12-23 Last updated: 2023-11-27Bibliographically approved
    2. Targeted proteome analysis of extracellular vesicles from gastric cancer cell lines
    Open this publication in new window or tab >>Targeted proteome analysis of extracellular vesicles from gastric cancer cell lines
    Show others...
    (English)Manuscript (preprint) (Other academic)
    Abstract [en]

    Gastric cancer (GC) is the third leading cause of cancer death. Early detection and efficient monitoring of tumor dynamics are prerequisites for reducing disease burden and mortality. Blood-based biomarker assays for the detection of early-stage GC could be of great relevance for population-wide or risk-group-based screening programs. Extracellular vesicles (EVs) are nano-sized membrane-enclosed particles released from all cells, which play an essential role as mediators of intercellular communication and are a promising class of biomarkers. We aimed to determine the putative panel of protein targets by collecting EVs from GC cell lines for future diagnostic assays. We measured levels of over 430 proteins using highly sensitive and high-throughput proximity extension assays (PEA). The protein network and function of each protein were analyzed. In conclusion, despite a similarity between GC EVs and EVs from the prostate as a control, we identified a set of 39 proteins in GC EVs that are involved in different cellular pathways and are not expressed or have low expression in exosomes from the prostate.

    Keywords
    Extracellular vesicles (EVs), Small Extracellular vesicles (sEVs), Seminal fluid extracellular vesicles (Prostasome), Proteomics, Proximity Extension Assay (PEA), Gastric Cancer
    National Category
    Medical Biotechnology (with a focus on Cell Biology (including Stem Cell Biology), Molecular Biology, Microbiology, Biochemistry or Biopharmacy)
    Research subject
    Biology with specialization in Molecular Cell Biology
    Identifiers
    urn:nbn:se:uu:diva-490598 (URN)
    Available from: 2022-12-13 Created: 2022-12-13 Last updated: 2023-02-02Bibliographically approved
    3. Increased levels of thymidine kinase 1 in malignant cell-derived extracellular vesicles
    Open this publication in new window or tab >>Increased levels of thymidine kinase 1 in malignant cell-derived extracellular vesicles
    Show others...
    2024 (English)In: Biochemistry and Biophysics Reports, ISSN 2405-5808, Vol. 39Article in journal (Refereed) Published
    Abstract [en]

    Extracellular vesicles (EVs), whose main subtypes are exosomes, microparticles, and apoptotic bodies, are secreted by all cells and harbor biomolecules such as DNA, RNA, and proteins. They function as intercellular messengers and, depending on their cargo, may have multiple roles in cancer development. Thymidine kinase 1 (TK1) is a cell cycle-dependent enzyme used as a biomarker for cell proliferation. TK1 is usually elevated in cancer patients' serum, making the enzyme a valuable tumor proliferation biomarker that strongly correlates with cancer stage and metastatic capabilities. Here, we investigated the presence of TK1 in EVs derived from three prostate cancer cell lines with various p53 mutation statuses (LNCaP, PC3, and DU145), EVs from the normal prostate epithelial cell line RWPE-1 and EVs isolated from human seminal fluid (prostasomes). We measured the TK1 activity by a real-time assay for these EVs. We demonstrated that the TK1 enzyme activity is higher in EVs derived from the malignant cell lines, with the highest activity from cells deriving from the most aggressive cancer, compared to the prostasomes and RWPE-1 EVs. The measurement of TK1 activity in EVs may be essential in future prostate cancer studies.

    Place, publisher, year, edition, pages
    Elsevier, 2024
    National Category
    Clinical Laboratory Medicine
    Identifiers
    urn:nbn:se:uu:diva-492203 (URN)10.1016/j.bbrep.2024.101761 (DOI)001259552100001 ()39006942 (PubMedID)
    Available from: 2023-01-03 Created: 2023-01-03 Last updated: 2024-08-12Bibliographically approved
    4. Image-based high-throughput mapping of TGF-beta-induced phosphocomplexes at a single-cell level
    Open this publication in new window or tab >>Image-based high-throughput mapping of TGF-beta-induced phosphocomplexes at a single-cell level
    Show others...
    2021 (English)In: Communications Biology, E-ISSN 2399-3642, Vol. 4, article id 1284Article in journal (Refereed) Published
    Abstract [en]

    To improve our ability to monitor cellular responses to e.g. cytokines or drugs, Lonn et al have developed a semi-automated system for large-scale in situ proximity ligation assays (isPLA) in HaCAT keratinocyte cells. Their approach expands the scope for image-based single cell analyses by combining observations of protein interactions and modifications with morphological details of individual cells at high throughput. Protein interactions and posttranslational modifications orchestrate cellular responses to e.g. cytokines and drugs, but it has been difficult to monitor these dynamic events in high-throughput. Here, we describe a semi-automated system for large-scale in situ proximity ligation assays (isPLA), combining isPLA in microtiter wells with automated microscopy and computer-based image analysis. Phosphorylations and interactions are digitally recorded along with subcellular morphological features. We investigated TGF-beta-responsive Smad2 linker phosphorylations and complex formations over time and across millions of individual cells, and we relate these events to cell cycle progression and local cell crowding via measurements of DNA content and nuclear size of individual cells, and of their relative positions. We illustrate the suitability of this protocol to screen for drug effects using phosphatase inhibitors. Our approach expands the scope for image-based single cell analyses by combining observations of protein interactions and modifications with morphological details of individual cells at high throughput.

    Place, publisher, year, edition, pages
    Springer NatureSpringer Nature, 2021
    National Category
    Medical Biotechnology (with a focus on Cell Biology (including Stem Cell Biology), Molecular Biology, Microbiology, Biochemistry or Biopharmacy)
    Identifiers
    urn:nbn:se:uu:diva-459770 (URN)10.1038/s42003-021-02798-4 (DOI)000718004600008 ()34773084 (PubMedID)
    Available from: 2021-11-30 Created: 2021-11-30 Last updated: 2024-01-15Bibliographically approved
    Download full text (pdf)
    UUThesis_E-Manouchehri-Doulabi-2023
    Download (jpg)
    presentationsbild
  • 19.
    Manouchehri Doulabi, Ehsan
    et al.
    Uppsala University, Science for Life Laboratory, SciLifeLab. Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology.
    Dubois, Louise
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Medical Sciences, Clinical Chemistry.
    Löf, Liza
    Uppsala University, Science for Life Laboratory, SciLifeLab. Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology.
    Sinha, Tanay Kumar
    Uppsala University, Science for Life Laboratory, SciLifeLab. Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology, Molecular Tools and Functional Genomics.
    Stålhandske, Per
    Biovica International AB.
    Larsson, Anders
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Medical Sciences, Clinical Chemistry.
    Kamali-Moghaddam, Masood
    Uppsala University, Science for Life Laboratory, SciLifeLab. Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology.
    Increased levels of thymidine kinase 1 in malignant cell-derived extracellular vesicles2024In: Biochemistry and Biophysics Reports, ISSN 2405-5808, Vol. 39Article in journal (Refereed)
    Abstract [en]

    Extracellular vesicles (EVs), whose main subtypes are exosomes, microparticles, and apoptotic bodies, are secreted by all cells and harbor biomolecules such as DNA, RNA, and proteins. They function as intercellular messengers and, depending on their cargo, may have multiple roles in cancer development. Thymidine kinase 1 (TK1) is a cell cycle-dependent enzyme used as a biomarker for cell proliferation. TK1 is usually elevated in cancer patients' serum, making the enzyme a valuable tumor proliferation biomarker that strongly correlates with cancer stage and metastatic capabilities. Here, we investigated the presence of TK1 in EVs derived from three prostate cancer cell lines with various p53 mutation statuses (LNCaP, PC3, and DU145), EVs from the normal prostate epithelial cell line RWPE-1 and EVs isolated from human seminal fluid (prostasomes). We measured the TK1 activity by a real-time assay for these EVs. We demonstrated that the TK1 enzyme activity is higher in EVs derived from the malignant cell lines, with the highest activity from cells deriving from the most aggressive cancer, compared to the prostasomes and RWPE-1 EVs. The measurement of TK1 activity in EVs may be essential in future prostate cancer studies.

    Download full text (pdf)
    fulltext
  • 20.
    Manouchehri Doulabi, Ehsan
    et al.
    Uppsala University, Science for Life Laboratory, SciLifeLab. Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology, Molecular Tools and Functional Genomics.
    Sinha, Tanay Kumar
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology, Molecular Tools and Functional Genomics. Uppsala University, Science for Life Laboratory, SciLifeLab.
    Löf, Liza
    Uppsala University, Science for Life Laboratory, SciLifeLab. Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology, Molecular Tools and Functional Genomics.
    Ikebuchi, Ryoyo
    Uppsala University, Science for Life Laboratory, SciLifeLab. Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology, Molecular Tools and Functional Genomics.
    Lindén, Sara
    Larsson, Anders
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Medical Sciences, Clinical Chemistry.
    Shen, Qiujin
    Uppsala University, Science for Life Laboratory, SciLifeLab. Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology, Molecular Tools and Functional Genomics.
    Kamali-Moghaddam, Masood
    Uppsala University, Science for Life Laboratory, SciLifeLab. Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology, Molecular Tools and Functional Genomics.
    Targeted proteome analysis of extracellular vesicles from gastric cancer cell linesManuscript (preprint) (Other academic)
    Abstract [en]

    Gastric cancer (GC) is the third leading cause of cancer death. Early detection and efficient monitoring of tumor dynamics are prerequisites for reducing disease burden and mortality. Blood-based biomarker assays for the detection of early-stage GC could be of great relevance for population-wide or risk-group-based screening programs. Extracellular vesicles (EVs) are nano-sized membrane-enclosed particles released from all cells, which play an essential role as mediators of intercellular communication and are a promising class of biomarkers. We aimed to determine the putative panel of protein targets by collecting EVs from GC cell lines for future diagnostic assays. We measured levels of over 430 proteins using highly sensitive and high-throughput proximity extension assays (PEA). The protein network and function of each protein were analyzed. In conclusion, despite a similarity between GC EVs and EVs from the prostate as a control, we identified a set of 39 proteins in GC EVs that are involved in different cellular pathways and are not expressed or have low expression in exosomes from the prostate.

  • 21.
    Mathieson, Iain
    et al.
    Univ Penn, Perelman Sch Med, Dept Genet, Philadelphia, PA 19104 USA..
    Day, Felix R.
    Univ Cambridge, Inst Metab Sci, MRC Epidemiol Unit, Cambridge, England..
    Barban, Nicola
    Alma Mater Studiorum Univ Bologna, Bologna, Italy..
    Tropf, Felix C.
    Univ Oxford, Nuffield Coll, Oxford, England.;ENSAE, Paris, France.;Ctr Res Econ & Stat CREST, Paris, France..
    Brazel, David M.
    Univ Oxford, Nuffield Coll, Oxford, England.;Univ Oxford, Leverhulme Ctr Demog Sci, Oxford, England..
    Vaez, Ahmad
    Univ Groningen, Univ Med Ctr Groningen, Dept Epidemiol, Groningen, Netherlands.;Isfahan Univ Med Sci, Dept Bioinformat, Esfahan, Iran..
    van Zuydam, Natalie
    Uppsala University, Science for Life Laboratory, SciLifeLab. Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology.
    Bitarello, Bárbara D.
    Univ Penn, Perelman Sch Med, Dept Genet, Philadelphia, PA 19104 USA..
    Gardner, Eugene J.
    Univ Cambridge, Inst Metab Sci, MRC Epidemiol Unit, Cambridge, England..
    Akimova, Evelina T.
    Univ Oxford, Nuffield Coll, Oxford, England.;Univ Oxford, Leverhulme Ctr Demog Sci, Oxford, England..
    Azad, Ajuna
    Univ Copenhagen, Fac Hlth & Med Sci, DNRF Ctr Chromosome Stabil, Dept Cellular & Mol Med, Copenhagen, Denmark..
    Bergmann, Sven
    Univ Lausanne, Dept Computat Biol, Lausanne, Switzerland.;Swiss Inst Bioinformat, Lausanne, Switzerland.;Univ Cape Town, Dept Integrat Biomed Sci, Cape Town, South Africa..
    Bielak, Lawrence F.
    Univ Michigan, Dept Epidemiol, Ann Arbor, MI USA..
    Boomsma, Dorret I.
    Vrije Univ Amsterdam, Amsterdam Publ Hlth Res Inst, Dept Biol Psychol, Amsterdam, Netherlands.;Amsterdam Reprod & Dev AR&D Res Inst, Amsterdam, Netherlands..
    Bosak, Kristina
    Psychiat Hosp Sveti Ivan, Zagreb, Croatia..
    Brumat, Marco
    Univ Trieste, Dept Med Surg & Hlth Sci, Trieste, Italy..
    Buring, Julie E.
    Brigham & Womens Hosp, Boston, MA USA.;Harvard Med Sch, Boston, MA USA..
    Cesarini, David
    NYU, Dept Econ, New York, NY USA.;Res Inst Ind Econ, Stockholm, Sweden.;Natl Bur Econ Res, Cambridge, MA USA..
    Chasman, Daniel I.
    Brigham & Womens Hosp, Boston, MA USA.;Harvard Med Sch, Boston, MA USA..
    Chavarro, Jorge E.
    Harvard Med Sch, Boston, MA USA.;Harvard TH Chan Sch Publ Hlth, Dept Epidemiol, Boston, MA USA.;Harvard TH Chan Sch Publ Hlth, Dept Nutr, Boston, MA USA.;Brigham & Womens Hosp, Channing Div Network Med, Giorgia Hamdi, Boston, MA USA..
    Cocca, Massimiliano
    IRCCS Burlo Garofolo, Inst Maternal & Child Hlth, Trieste, Italy..
    Concas, Maria Pina
    IRCCS Burlo Garofolo, Inst Maternal & Child Hlth, Trieste, Italy..
    Davey Smith, George
    Univ Bristol, MRC Integrat Epidemiol Unit, Bristol, Avon, England..
    Davies, Gail
    Univ Edinburgh, Dept Psychol, Lothian Birth Cohorts, Edinburgh, Midlothian, Scotland..
    Deary, Ian J.
    Univ Edinburgh, Dept Psychol, Lothian Birth Cohorts, Edinburgh, Midlothian, Scotland..
    Esko, Tõnu
    Univ Tartu, Estonian Genome Ctr, Tartu, Estonia.;MIT, Broad Inst, Cambridge, MA USA.;Harvard Univ, Cambridge, MA USA..
    Faul, Jessica D.
    Univ Michigan, Inst Social Res, Survey Res Ctr, Ann Arbor, MI USA..
    Franco, Oscar
    Erasmus MC, Univ Med Ctr Rotterdam, Dept Epidemiol, Rotterdam, Netherlands.;Univ Utrecht, Univ Med Ctr Utrecht, Julius Ctr Hlth Sci & Primary Care, Utrecht, Netherlands..
    Ganna, Andrea
    Univ Helsinki, FIMM, HiLIFE, Helsinki, Finland.;Massachusetts Gen Hosp, Ctr Genom Med, Analyt & Translat Genet Unit, Boston, MA USA..
    Gaskins, Audrey J.
    Emory Univ, Rollins Sch Publ Hlth, Dept Epidemiol, Atlanta, GA USA..
    Gelemanovic, Andrea
    Univ Split, Sch Med, Split, Croatia..
    de Geus, Eco J. C.
    Vrije Univ Amsterdam, Amsterdam Publ Hlth Res Inst, Dept Biol Psychol, Amsterdam, Netherlands..
    Gieger, Christian
    German Res Ctr Environm Hlth, Helmholtz Zentrum Munchen, Res Unit Mol Epidemiol, Neuherberg, Germany..
    Girotto, Giorgia
    Univ Trieste, Dept Med Surg & Hlth Sci, Trieste, Italy.;IRCCS Burlo Garofolo, Inst Maternal & Child Hlth, Trieste, Italy..
    Gopinath, Bamini
    Univ Sydney, Westmead Inst Med Res, Ctr Vis Res, Sydney, NSW, Australia.;Univ Sydney, Dept Ophthalmol, Sydney, NSW, Australia..
    Grabe, Hans Jörgen
    Univ Med Greifswald, Dept Psychiat & Psychotherapy, Greifswald, Germany..
    Gunderson, Erica P.
    Kaiser Permanente Northern Calif, Div Res, Oakland, CA USA..
    Hayward, Caroline
    Univ Edinburgh, Inst Genet & Canc, Med Res Council Human Genet Unit, Edinburgh, Midlothian, Scotland..
    He, Chunyan
    Univ Kentucky, Markey Canc Ctr, Lexington, KY USA.;Univ Kentucky, Dept Internal Med, Div Med Oncol, Coll Med, Lexington, KY USA..
    van Heemst, Diana
    Leiden Univ, Dept Internal Med, Sect Gerontol & Geriatr, Med Ctr, Leiden, Netherlands..
    Hill, W. David
    Univ Edinburgh, Dept Psychol, Lothian Birth Cohorts, Edinburgh, Midlothian, Scotland..
    Hoffmann, Eva R.
    Univ Copenhagen, Fac Hlth & Med Sci, DNRF Ctr Chromosome Stabil, Dept Cellular & Mol Med, Copenhagen, Denmark..
    Homuth, Georg
    Univ Greifswald, Interfac Inst Genet & Funct Genom, Greifswald, Germany..
    Hottenga, Jouke Jan
    Vrije Univ Amsterdam, Amsterdam Publ Hlth Res Inst, Dept Biol Psychol, Amsterdam, Netherlands..
    Huang, Hongyang
    Harvard TH Chan Sch Publ Hlth, Dept Epidemiol, Boston, MA USA..
    Hyppönen, Elina
    Univ South Australia, Australian Ctr Precis Hlth, Canc Res Inst, Adelaide, SA, Australia.;South Australian Hlth & Med Res Inst, Adelaide, SA, Australia..
    Ikram, M. Arfan
    Erasmus MC, Univ Med Ctr Rotterdam, Dept Epidemiol, Rotterdam, Netherlands..
    Jansen, Rick
    Vrije Univ, Dept Psychiat, Amsterdam Publ Hlth & Amsterdam Neurosci, Amsterdam UMC, Amsterdam, Netherlands..
    Johannesson, Magnus
    Stockholm Sch Econ, Dept Econ, Stockholm, Sweden..
    Kamali, Zoha
    Univ Groningen, Univ Med Ctr Groningen, Dept Epidemiol, Groningen, Netherlands.;Isfahan Univ Med Sci, Dept Bioinformat, Esfahan, Iran..
    Kardia, Sharon L. R.
    Univ Michigan, Dept Epidemiol, Ann Arbor, MI USA..
    Kavousi, Maryam
    Erasmus MC, Univ Med Ctr Rotterdam, Dept Epidemiol, Rotterdam, Netherlands..
    Kifley, Annette
    Univ Sydney, Westmead Inst Med Res, Ctr Vis Res, Sydney, NSW, Australia.;Univ Sydney, Dept Ophthalmol, Sydney, NSW, Australia..
    Kiiskinen, Tuomo
    Univ Helsinki, FIMM, HiLIFE, Helsinki, Finland.;Natl Inst Hlth & Welf, Helsinki, Finland..
    Kraft, Peter
    Harvard TH Chan Sch Publ Hlth, Dept Epidemiol, Boston, MA USA.;Harvard TH Chan Sch Publ Hlth, Dept Biostat, Boston, MA USA..
    Kuehnel, Brigitte
    German Res Ctr Environm Hlth, Helmholtz Zentrum Munchen, Res Unit Mol Epidemiol, Neuherberg, Germany..
    Langenberg, Claudia
    Univ Cambridge, Inst Metab Sci, MRC Epidemiol Unit, Cambridge, England..
    Liew, Gerald
    Univ Sydney, Westmead Inst Med Res, Ctr Vis Res, Sydney, NSW, Australia.;Univ Sydney, Dept Ophthalmol, Sydney, NSW, Australia..
    Lind, Penelope A.
    QIMR Berghofer Med Res Inst, Psychiat Genet, Brisbane, Qld, Australia..
    Luan, Jian'an
    Univ Cambridge, Inst Metab Sci, MRC Epidemiol Unit, Cambridge, England..
    Mägi, Reedik
    Univ Tartu, Estonian Genome Ctr, Tartu, Estonia..
    Magnusson, Patrik K. E.
    Karolinska Inst, Dept Med Epidemiol & Biostat, Stockholm, Sweden..
    Mahajan, Anubha
    Univ Oxford, Wellcome Ctr Human Genet, Oxford, England.;Univ Oxford, Oxford Ctr Diabet Endocrinol & Metab, Radcliffe Dept Med, Oxford, England..
    Martin, Nicholas G.
    QIMR Berghofer Med Res Inst, Genet Epidemiol, Brisbane, Qld, Australia..
    Mbarek, Hamdi
    Vrije Univ Amsterdam, Amsterdam Publ Hlth Res Inst, Dept Biol Psychol, Amsterdam, Netherlands.;Qatar Fdn, Qatar Fdn Res, Qatar Genome Programme, Dev & Innovat, Doha, Qatar..
    McCarthy, Mark I.
    Univ Oxford, Wellcome Ctr Human Genet, Oxford, England.;Univ Oxford, Oxford Ctr Diabet Endocrinol & Metab, Radcliffe Dept Med, Oxford, England..
    McMahon, George
    Univ Bristol, Sch Social & Community Med, Bristol, Avon, England..
    Medland, Sarah E.
    QIMR Berghofer Med Res Inst, Psychiat Genet, Brisbane, Qld, Australia..
    Meitinger, Thomas
    German Res Ctr Environm Hlth, Inst Human Genet, Helmholtz Zent Munchen, Neuherberg, Germany..
    Metspalu, Andres
    Univ Tartu, Estonian Genome Ctr, Tartu, Estonia.;Univ Tartu, Inst Mol & Cell Biol, Tartu, Estonia..
    Mihailov, Evelin
    Univ Tartu, Estonian Genome Ctr, Tartu, Estonia..
    Milani, Lili
    Univ Tartu, Estonian Genome Ctr, Tartu, Estonia..
    Missmer, Stacey A.
    Harvard TH Chan Sch Publ Hlth, Dept Epidemiol, Boston, MA USA.;Boston Childrens Hosp, Div Adolescent & Young Adult Med, Dept Med, Boston, MA USA.;Michigan State Univ, Coll Human Med, Dept Obstet Gynecol & Reprod Biol, Grand Rapids, MI USA..
    Mitchell, Paul
    Univ Sydney, Westmead Inst Med Res, Ctr Vis Res, Sydney, NSW, Australia.;Univ Sydney, Dept Ophthalmol, Sydney, NSW, Australia..
    Mollegaard, Stine
    Univ Copenhagen, Dept Sociol, Copenhagen, Denmark..
    Mook-Kanamori, Dennis O.
    Leiden Univ, Dept Clin Epidemiol, Med Ctr, Leiden, Netherlands.;Leiden Univ, Dept Publ Hlth & Primary Care, Med Ctr, Leiden, Netherlands..
    Morgan, Anna
    IRCCS Burlo Garofolo, Inst Maternal & Child Hlth, Trieste, Italy..
    van der Most, Peter
    Univ Groningen, Univ Med Ctr Groningen, Dept Epidemiol, Groningen, Netherlands..
    de Mutsert, Renee
    Leiden Univ, Dept Clin Epidemiol, Med Ctr, Leiden, Netherlands..
    Nauck, Matthias
    Univ Med Greifswald, Inst Clin Chem & Lab Med, Greifswald, Germany..
    Nolte, Ilja M.
    Univ Groningen, Univ Med Ctr Groningen, Dept Epidemiol, Groningen, Netherlands..
    Noordam, Raymond
    Leiden Univ, Dept Internal Med, Sect Gerontol & Geriatr, Med Ctr, Leiden, Netherlands..
    Penninx, Brenda W. J. H.
    Vrije Univ Amsterdam, EMGO Inst Hlth & Care Res, Dept Psychiat, Med Ctr,GGZ inGeest, Amsterdam, Netherlands.;Vrije Univ Amsterdam, Neurosci Campus Amsterdam, Med Ctr, GGZ inGeest, Amsterdam, Netherlands..
    Peters, Annette
    German Res Ctr Environm Hlth, Inst Epidemiol, Helmholtz Zent Munchen, Neuherberg, Germany..
    Peyser, Patricia A.
    Univ Michigan, Dept Epidemiol, Ann Arbor, MI USA..
    Polasek, Ozren
    Univ Split, Sch Med, Split, Croatia.;Algebra Univ Coll, Zagreb, Croatia..
    Power, Chris
    UCL Great Ormond St Inst Child Hlth, Populat Policy & Practice Res & Teaching Dept, London, England..
    Pribisalic, Ajka
    Univ Split, Sch Med, Split, Croatia..
    Redmond, Paul
    Univ Edinburgh, Dept Psychol, Lothian Birth Cohorts, Edinburgh, Midlothian, Scotland..
    Rich-Edwards, Janet W.
    Harvard Med Sch, Boston, MA USA.;Harvard TH Chan Sch Publ Hlth, Dept Epidemiol, Boston, MA USA.;Brigham & Womens Hosp, Channing Div Network Med, Giorgia Hamdi, Boston, MA USA.;Brigham & Womens Hosp, Div Womens Hlth, Dept Med, Boston, MA USA..
    Ridker, Paul M.
    Brigham & Womens Hosp, Boston, MA USA.;Harvard Med Sch, Boston, MA USA..
    Rietveld, Cornelius A.
    Erasmus Univ, Rotterdam Inst Behav & Biol, Rotterdam, Netherlands.;Erasmus Sch Econ, Dept Appl Econ, Rotterdam, Netherlands..
    Ring, Susan M.
    Univ Bristol, MRC Integrat Epidemiol Unit, Bristol, Avon, England..
    Rose, Lynda M.
    Brigham & Womens Hosp, Boston, MA USA..
    Rueedi, Rico
    Univ Lausanne, Dept Computat Biol, Lausanne, Switzerland.;Swiss Inst Bioinformat, Lausanne, Switzerland..
    Shukla, Vallari
    Univ Copenhagen, Fac Hlth & Med Sci, DNRF Ctr Chromosome Stabil, Dept Cellular & Mol Med, Copenhagen, Denmark..
    Smith, Jennifer A.
    Univ Michigan, Dept Epidemiol, Ann Arbor, MI USA.;Univ Michigan, Inst Social Res, Survey Res Ctr, Ann Arbor, MI USA..
    Stankovic, Stasa
    Univ Cambridge, Inst Metab Sci, MRC Epidemiol Unit, Cambridge, England..
    Stefansson, Kari
    deCODE Genet Amgen Inc, Reykjavik, Iceland..
    Stöckl, Doris
    German Res Ctr Environm Hlth, Inst Epidemiol, Helmholtz Zent Munchen, Neuherberg, Germany..
    Strauch, Konstantin
    Johannes Gutenberg Univ Mainz, Univ Med Ctr, IMBEI, Mainz, Germany.;German Res Ctr Environm Hlth, Helmholtz Zentrum Munchen, Inst Genet Epidemiol, Neuherberg, Germany.;LMU, Fac Med, Chair Genet Epidemiol, IBE, Munich, Germany..
    Swertz, Morris A.
    Univ Groningen, Univ Med Ctr Groningen, Dept Genet, Groningen, Netherlands..
    Teumer, Alexander
    Univ Med Greifswald, Inst Community Med, Greifswald, Germany..
    Thorleifsson, Gudmar
    deCODE Genet Amgen Inc, Reykjavik, Iceland..
    Thorsteinsdottir, Unnur
    deCODE Genet Amgen Inc, Reykjavik, Iceland..
    Thurik, A. Roy
    Erasmus Univ, Rotterdam Inst Behav & Biol, Rotterdam, Netherlands.;Erasmus Sch Econ, Dept Appl Econ, Rotterdam, Netherlands.;Montpellier Business Sch, Montpellier, France..
    Timpson, Nicholas J.
    Univ Bristol, MRC Integrat Epidemiol Unit, Bristol, Avon, England..
    Turman, Constance
    Harvard TH Chan Sch Publ Hlth, Dept Epidemiol, Boston, MA USA..
    Uitterlinden, André G.
    Erasmus Univ, Rotterdam Inst Behav & Biol, Rotterdam, Netherlands.;Erasmus MC, Univ Med Ctr Rotterdam, Dept Internal Med, Rotterdam, Netherlands..
    Waldenberger, Melanie
    German Res Ctr Environm Hlth, Helmholtz Zentrum Munchen, Res Unit Mol Epidemiol, Neuherberg, Germany.;German Res Ctr Environm Hlth, Inst Epidemiol, Helmholtz Zent Munchen, Neuherberg, Germany..
    Wareham, Nicholas J.
    Univ Cambridge, Inst Metab Sci, MRC Epidemiol Unit, Cambridge, England..
    Weir, David R.
    Univ Michigan, Inst Social Res, Survey Res Ctr, Ann Arbor, MI USA..
    Willemsen, Gonneke
    Vrije Univ Amsterdam, Amsterdam Publ Hlth Res Inst, Dept Biol Psychol, Amsterdam, Netherlands..
    Zhao, Jing Hau
    Univ Cambridge, Inst Metab Sci, MRC Epidemiol Unit, Cambridge, England..
    Zhao, Wei
    Univ Michigan, Dept Epidemiol, Ann Arbor, MI USA..
    Zhao, Yajie
    Univ Cambridge, Inst Metab Sci, MRC Epidemiol Unit, Cambridge, England..
    Snieder, Harold
    Univ Groningen, Univ Med Ctr Groningen, Dept Epidemiol, Groningen, Netherlands..
    den Hoed, Marcel
    Uppsala University, Science for Life Laboratory, SciLifeLab. Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology, Molecular Tools and Functional Genomics.
    Ong, Ken K.
    Univ Cambridge, Inst Metab Sci, MRC Epidemiol Unit, Cambridge, England..
    Mills, Melinda C.
    Univ Oxford, Nuffield Coll, Oxford, England.;Univ Oxford, Leverhulme Ctr Demog Sci, Oxford, England.;Univ Groningen, Univ Med Ctr Groningen, Dept Genet, Groningen, Netherlands.;Univ Groningen, Dept Econ Econometr & Finance, Groningen, Netherlands..
    Perry, John R. B.
    Univ Cambridge, Inst Metab Sci, MRC Epidemiol Unit, Cambridge, England..
    Genome-wide analysis identifies genetic effects on reproductive success and ongoing natural selection at the FADS locus2023In: Nature Human Behaviour, E-ISSN 2397-3374, Vol. 7, no 5, p. 790-801Article in journal (Refereed)
    Abstract [en]

    Identifying genetic determinants of reproductive success may highlight mechanisms underlying fertility and identify alleles under present-day selection. Using data in 785,604 individuals of European ancestry, we identified 43 genomic loci associated with either number of children ever born (NEB) or childlessness. These loci span diverse aspects of reproductive biology, including puberty timing, age at first birth, sex hormone regulation, endometriosis and age at menopause. Missense variants in ARHGAP27 were associated with higher NEB but shorter reproductive lifespan, suggesting a trade-off at this locus between reproductive ageing and intensity. Other genes implicated by coding variants include PIK3IP1, ZFP82 and LRP4, and our results suggest a new role for the melanocortin 1 receptor (MC1R) in reproductive biology. As NEB is one component of evolutionary fitness, our identified associations indicate loci under present-day natural selection. Integration with data from historical selection scans highlighted an allele in the FADS1/2 gene locus that has been under selection for thousands of years and remains so today. Collectively, our findings demonstrate that a broad range of biological mechanisms contribute to reproductive success.

  • 22.
    Mattisson, Jonas
    Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology, Molecular Tools and Functional Genomics.
    The role of hematopoietic chromosome Y loss in health and disease2023Doctoral thesis, comprehensive summary (Other academic)
    Abstract [en]

    Mosaic loss of chromosome Y (mLOY) is the most common somatic mutation, and affected men have increased risk for all major causes of death, including cardiovascular diseases and cancer. As a male specific mutation, it helps explain why men live shorter lives than women. However, the causality is debated, and contrasting models have been proposed to explain how Y loss in blood could be linked with disease in other organs. In this thesis, I provide results contributing to this debate.

    In Paper I, we identify 156 loci associated with genetic susceptibility for mLOY. Enrichment of loci involved in processes such as cell-cycle regulation and cancer susceptibility suggest that mLOY could be viewed as a barometer of genomic instability. 

    In Paper II, we used the mLOY-associated variants identified in Paper I to calculate a PRS for mLOY in an independent cohort. We found that men with high PRS displayed a five-fold increased risk in an age dependent manner.

    In Paper III, we showed that mLOY and CHIP driving SNVs often co-occur in leukocytes. Considering that they share clinical manifestations, further studies are necessary to elucidate how these mutations contributes to disease risk.  

    In Paper IV, we studied transcriptional effects of mLOY in leukocytes and identified almost 500 dysregulated autosomal genes, varying between cell types. We also report that mLOY in specific leukocytes might be linked with different types of disease.  

    In Paper V, regulatory T cells are shown to be affected with Y loss to a greater extent than other CD4+ T lymphocytes. We propose that mLOY might drive T lymphocytes towards the regulatory phenotype, known to exhibit immunosuppressive functions. 

    In Paper VI, we used CITE-seq to show that expression and cell surface abundance of the immunoprotein CD99 is lower in leukocytes with Y loss. This finding provides a possible explanation how mLOY could influence normal immune response, since CD99 is essential is for the mobility and cell-to-cell interactions of leukocytes. 

    In Paper VII, it is shown that hematological mLOY cause disease directly in other organs. Mice with mLOY was shown to have a reduced survival, increased fibrosis and cardiac dysfunction, while men in UK biobank with mLOY in blood was found to die from diseases of the circulatory system in a dose dependent manner. Treatment with TGFβ1-inhibitors could restore cardiac function in mLOY-mice. 

    Together, the presented results show that mLOY both reflect genomic instability overall, while also causing disease directly.

    List of papers
    1. Genetic predisposition to mosaic Y chromosome loss in blood
    Open this publication in new window or tab >>Genetic predisposition to mosaic Y chromosome loss in blood